Our results suggest that the genes regulated by IL-17 in RHE are likely relevant to the effects of IL-17 in psoriasis, since ixekizumab strongly suppressed these “RHE” genes in psoriasis patients treated in vivo with this IL-17 antagonist. The gene discussed is IL17A; the disease is psoriasis.